AI assistant
ALTECH BATTERIES LTD — Capital/Financing Update 2016
Jun 8, 2016
64444_rns_2016-06-08_6b491817-903c-4240-bc71-046a659e698b.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [572 x 148] intentionally omitted <==
9 June 2016
Notice under Section 708A(5)(e) of the Corporations Act
On 9 June 2016, Altech Chemicals Limited ( Company ) issued 500,000 fully paid ordinary shares ( Shares ) upon the exercise of unlisted options (Exp. 30 June 2016, Ex $0.10), to persons who fall within one of the exemptions set out in section 708 of the Corporations Act.
The Company gives this notice pursuant to Section 708A(5)(e) of the Corporations Act.
The shares were issued without disclosure to investors under Part 6D.2, in reliance on Section 708A(5) of the Corporations Act.
The Company, as at the date of this notice, has complied with:
-
(a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
-
(b) Section 674 of the Corporations Act.
There is no excluded information for the purposes of Sections 708A(7) and (8) of the Corporations Act.
Yours faithfully
==> picture [86 x 50] intentionally omitted <==
Shane Volk Company Secretary
Altech Chemicals Limited
Rule
2.7,
3.10.3,
3.10.4,
3.10.5
**Appendix
3B**
**New
issue
announcement, application
for
quotation
of
additional
securities and
agreement**
Information
or
documents
not
available
now
must
be
given
to
ASX
as
soon
as
available.
Information
and documents
given
to
ASX
become
ASX’s
property
and
may
be
made
public.
Introduced
01/07/96
Origin:
Appendix
5
Amended
01/07/98,
01/09/99,
01/07/00,
30/09/01,
11/03/02,
01/01/03,
24/10/05,
01/08/12
9
June
2016
Name
of
entity
Altech
Chemicals
Limited
ABN 45
125
301
206
We
(the
entity)
give
ASX
the
following
information.
**Part
1
-‐
All
issues**
| Part 1 - All issues | Part 1 - All issues | ||||
|---|---|---|---|---|---|
You must complete the relevant sections (attach sheets if there is not enough space). |
|||||
| 1 | +Class of+securities issued or to be issued |
ordinary shares |
|||
| 2 | Number of+securities issued or to be | ||||
| issued (if known) or maximum |
500,000 ordinary shares | ||||
| number which may be issued | |||||
| 3 | Principal terms of the+securities (eg, if options, exercise price and expiry date; if partly paid+securities, the amount outstanding and due dates for |
500,000 fully paid ordinary shares upon the exercise of unlisted options. |
|||
| payment; if+convertible securities, | |||||
| the conversion price and dates for | |||||
| conversion) |
- See
chapter
19
for
defined
terms.
01/08/2012
Appendix
3B
Page
2
| 4 Do the+securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 5 Issue price or consideration 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) 6a Is the entity an+eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h_in_ relation to the+securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder resolution under rule 7.1A was passed 6c Number of+securities issued without security holder approval under rule 7.1 |
Yes |
|---|---|
| $0.10 per share |
|
| For detailed design of the Company’s proposed HPA plant, finalising debt financing and for general working capital purposes. |
|
| Yes | |
| 15 October 2015 | |
| Nil |
- See
chapter
19
for
defined
terms.
01/08/2012
Appendix
3B
Page
3
| 6d Number of+securities issued with security holder approval under rule 7.1A 6e Number of+securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) 6f Number of securities issued under an exception in rule 7.2 6g If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation. 6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements 6i Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements 7 Dates of entering +securities into uncertificated holdings or despatch of certificates 8 Number and+class of all+securities quoted on ASX (including the securities in section 2 if applicable) |
nil | |
|---|---|---|
| nil | ||
| 500,000 | ||
| n/a | ||
| nil | ||
| 7.1: 10,262,767 7.1A: 16,351,696 |
||
| 9 June, 2016 | ||
| Number | ~~+~~Class | |
| 177,781,733 |
Ordinary Shares |
|
- See
chapter
19
for
defined
terms.
01/08/2012
Appendix
3B
Page
4
| ASX ANNOUNCEMENT AND MEDIA 9 Number and+class of all+securities not quoted on ASX (_including_the securities in section 2 if applicable) 10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) |
||
|---|---|---|
| Number | +Class | |
| RELEASE 2,000,000 1,000,000 1,000,000 1,000,000 600,000 3,800,000 10,000,000 3,500,000 |
Ex. $0.10, Expiry 30-06-2016 Ex. $0.20, Expiry 18-12-2017 Ex. $0.25, Expiry 18-12-2017 Ex. $0.30, Expiry 18-12-2017 Ex. $0.20, Expiry 31-01-2017 Performance Rights: Employees & Consultants Performance Rights: Managing Director Performance Rights: Directors |
|
| n/a |
**Part
2
-‐
Bonus
issue
or
pro
rata
issue**
| 11 Is security holder approval required? 12 Is the issue renounceable or non- renounceable? 13 Ratio in which the+securities will be offered 14 +Class of+securities to which the offer relates 15 +Record date to determine entitlements 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? 17 Policy for deciding entitlements in relation to fractions 18 Names of countries in which the entity has+security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. |
|
|---|---|
19 Closing date for receipt of acceptances or renunciations 20 Names of any underwriters 21 Amount of any underwriting fee or commission 22 Names of any brokers to the issue 23 Fee or commission payable to the broker to the issue 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of+security holders 25 If the issue is contingent on+security holders’ approval, the date of the meeting 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders 28 Date rights trading will begin (if applicable) 29 Date rights trading will end (if applicable) 30 How do+security holders sell their entitlements_in full_through a broker? 31 How do+security holders sell_part_of their entitlements through a broker and accept for the balance? |
|
|---|---|
- See
chapter
19
for
defined
terms.
01/08/2012
Appendix
3B
Page
6
-
32 How
do[+] security
holders
dispose
of their
entitlements
(except
by
sale through
a
broker)? -
33 +Despatch
date
**Part
3
-‐
Quotation
of
securities**
You
need
only
complete
this
section
if
you
are
applying
for
quotation
of
securities
-
34 Type
of
securities ( tick
one ) -
(a) ü[Securities
described
in
Part
1
] -
(b) All
other
securities
Example:
restricted
securities
at
the
end
of
the
escrowed
period,
partly
paid
securities
that
become
fully
paid, employee
incentive
share
securities
when
restriction
ends,
securities
issued
on
expiry
or
conversion
of
convertible securities
**Entities
that
have
ticked
box
34(a)**
**Additional
securities
forming
a
new
class
of
securities**
Tick
to
indicate
you
are
providing
the
information
or documents
-
35 If
the[+] securities
are[+] equity
securities,
the
names
of
the
20
largest
holders
of
the additional[+] securities,
and
the
number
and
percentage
of
additional[+] securities held
by
those
holders -
36 If
the[+] securities
are[+] equity
securities,
a
distribution
schedule
of
the
additional +securities
setting
out
the
number
of
holders
in
the
categories 1
-‐
1,000 -
1,001
-‐
5,000 -
5,001
-‐
10,000 10,001
-‐
100,000 -
100,001
and
over -
37 A
copy
of
any
trust
deed
for
the
additional[+] securities -
See
chapter
19
for
defined
terms.
01/08/2012
Appendix
3B
Page
7
**Entities
that
have
ticked
box
34(b)**
| 38 Number of securities for which +quotation is sought 39 Class of +securities for which quotation is sought 40 Do the+securities rank equally in all respects from the date of allotment with an existing+class of quoted+securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security) 42 Number and +class of all +securities quoted on ASX (_including_the securities in clause 38) |
||
|---|---|---|
| Number | +Class | |
- See
chapter
19
for
defined
terms.
01/08/2012
Appendix
3B
Page
8
**Quotation
agreement**
-
1 +Quotation
of
our
additional +securities
is
in
ASX’s
absolute
discretion.
ASX may
quote
the[+] securities
on
any
conditions
it
decides. -
2 We
warrant
the
following
to
ASX. -
The
issue
of
the[+] securities
to
be
quoted
complies
with
the
law
and
is not
for
an
illegal
purpose. -
There
is
no
reason
why
those[+] securities
should
not
be
granted + quotation. -
An
offer
of
the[+] securities
for
sale
within
12
months
after
their
issue will
not
require
disclosure
under
section
707(3)
or
section
1012C(6)
of the
Corporations
Act.
Note:
An
entity
may
need
to
obtain
appropriate
warranties
from
subscribers
for
the
securities
in
order
to
be able
to
give
this
warranty
-
Section
724
or
section
1016E
of
the
Corporations
Act
does
not
apply
to any
applications
received
by
us
in
relation
to
any[+] securities
to
be quoted
and
that
no-‐one
has
any
right
to
return
any[+] securities
to
be quoted
under
sections
737,
738
or
1016F
of
the
Corporations
Act
at
the time
that
we
request
that
the[+] securities
be
quoted. -
If
we
are
a
trust,
we
warrant
that
no
person
has
the
right
to
return
the +securities
to
be
quoted
under
section
1019B
of
the
Corporations
Act
at the
time
that
we
request
that
the[+] securities
be
quoted. -
3 We
will
indemnify
ASX
to
the
fullest
extent
permitted
by
law
in
respect
of
any claim,
action
or
expense
arising
from
or
connected
with
any
breach
of
the warranties
in
this
agreement. -
4 We
give
ASX
the
information
and
documents
required
by
this
form.
If
any information
or
document
not
available
now,
will
give
it
to
ASX
before +quotation
of
the +securities
begins.
We
acknowledge
that
ASX
is
relying
on the
information
and
documents.
We
warrant
that
they
are
(will
be)
true
and complete.
Sign
here: Date:
9
June
2016
( ~~Director/~~ Company
Secretary) Print
name: Shane
Volk
==
==
==
==
==
- See
chapter
19
for
defined
terms.
01/08/2012
Appendix
3B
Page
9
**Appendix
3B
–
Annexure
1**
**Calculation
of
placement
capacity
under
rule
7.1
and rule
7.1A
for[+] eligible
entities**
Introduced
01/08/12
**Part
1**
Rule 7.1 – Issues exceeding 15% of capital
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated
| Part 1 |
Part 1 |
|---|---|
| Rule 7.1 – Issues exceeding 15% of capital | |
| Step 1: Calculate “A”, the base figure from which the placement capacity is calculated |
|
| Insertnumber of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue |
112,013,117 |
| Addthe following: • Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2 • Number of fully paid ordinary securities issued in that 12 month period with shareholder approval • Number of partly paid ordinary securities that became fully paid in that 12 month period Note: • Include only ordinary securities here – other classes of equity securities cannot be added • Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed • It may be useful to set out issues of securities on different dates as separate line items |
50,000 (Vest Performance Rights 4/8/15) 8,974,576 (Placement 11/08/15 approved by shareholders 15/10/15) 5,052,100 (Vest Performance Rights 25/8/15) 6,779,663 (Convert various loan amounts to equity 24/9/15, approved by shareholders 15/10/15) 28,750 (Convert listed options 7/10/15) 55,600 (Vest Performance Rights 8/10/15) 8,474,577 (Placement 19/10/15 approved by shareholders 15/10/15) 7,033,902 (Convert various loan amounts to equity 26/10/15, approved by shareholders 15/10/15) 1,694,915 (Placement 10/11/2015 approved by shareholders 15/10/15) 137,166 (Convert listed options 3/12/15) 171,666 (Convert listed options 15/12/15) 199,750 (Convert listed options 17/12/15) 1,950,000 (Vest Employee Performance Rights 5/1/16) 1,750,000 (Vest NED Performance Rights 5/1/16) 8,651,175 (Share Purchase Plan 12/4/16) 500,000 (Convert Options 9/6/16) |
| Subtractthe number of fully paid ordinary securities cancelled during that 12 month period |
Nil |
| “A” | 163,516,957 |
- See
chapter
19
for
defined
terms.
01/08/2012
Appendix
3B
Page
10
Step 2: Calculate 15% of “A”
| Step 2: Calculate 15% of “A” | Step 2: Calculate 15% of “A” |
|---|---|
| “B” | 0.15 [Note: this value cannot be changed] |
| Multiply“A” by 0.15 | 24,527,544 |
| Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used |
|
| Insertnumber of equity securities issued or agreed to be issued in that 12 month period not counting_those issued: • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 _Note: • This applies to equity securities, unless specifically excluded – not just ordinary securities • Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed • It may be useful to set out issues of securities on different dates as separate line items |
14,264,776 (Placement @ 0.086)(5 April 2016) |
| “C” | 14,264,776 |
| Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1 |
|
| “A” x 0.15 Note: number must be same as shown in Step 2 |
24,527,544 |
| Subtract“C” Note: number must be same as shown in Step 3 |
(14,264,776) |
| Total[“A” x 0.15] – “C” | 10,262,767 [Note: this is the remaining placement capacity under rule 7.1] |
| Step 4: Subtract “C” from [“A” x “B”] to calculate remaining | Step 4: Subtract “C” from [“A” x “B”] to calculate remaining |
|---|---|
| placement capacity under rule 7.1 | |
| “A” x 0.15 | 24,527,544 |
| Note: number must be same as shown in | |
| Step 2 | |
| Subtract“C” | (14,264,776) |
| Note: number must be same as shown in | |
| Step 3 | |
| Total[“A” x 0.15] – “C” | 10,262,767 |
| [Note: this is the remaining placement | |
| capacity under rule 7.1] | |
- See
chapter
19
for
defined
terms.
01/08/2012
Appendix
3B
Page
11
Part 2
Part 2 |
Part 2 |
|---|---|
| Rule 7.1A – Additional placement capacity for eligible entities | |
| Step 1: Calculate “A”, the base figure from which the placement capacity is calculated |
|
| “A” Note: number must be same as shown in Step 1 of Part 1 |
163,516,957 |
| Step 2: Calculate 10% of “A” | |
| “D” | 0.10 Note: this value cannot be changed |
| Multiply“A” by 0.10 | 16,351,696 |
| Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used |
|
| Insertnumber of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: • This applies to equity securities – not just ordinary securities • Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed • Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained • It may be useful to set out issues of securities on different dates as separate line items |
|
| “E” | - |
- See
chapter
19
for
defined
terms.
01/08/2012
Appendix
3B
Page
12
| Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A |
|
| “A” x 0.10 Note: number must be same as shown in Step 2 |
16,351,696 |
| Subtract“E” Note: number must be same as shown in Step 3 |
- |
| Total[“A” x 0.10] – “E” | 16,351,696 Note: this is the remaining placement capacity under rule 7.1A |
- See
chapter
19
for
defined
terms.
01/08/2012
Appendix
3B
Page
13